← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-11 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,486개
ADCBiologicstaleAbbViePhase 2

Mirvetuximab Soravtansine-gynx (Mirvetuximab Soravtansine-gynx)

Ovary Cancer; Peritoneal Cancer · Ovary Cancer

#OvaryCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
AntibodystaleAustralasian Gastro-Intestinal …Phase 3

Mitomycin C; Capecitabine; Bevacizumab (Mitomycin C; Capecitabine; Bevacizumab)

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
CGTBiologicstaleXuzhou Medical UniversityPhase 2

Mixed CAR-T Transfer (Mixed CAR-T Transfer)

Hematopoietic/Lymphoid Cancer · Hematopoietic/Lymphoid Cancer

#HematopoieticLymphoidCancer#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
AntibodystaleAssistance Publique Hopitaux De…Phase 2

IPH2201 (Monalizumab, Monalizumab (IPH2201))

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
ADCBiologicstaleThe First Affiliated Hospital o…Phase 1

Monomethyl Auristatin E (MMAE, Monomethyl Auristatin E, Monomethyl Auristatin E (MMAE) / autologous neutrophil biological agents)

Unresectable Pancreatic Cancer · Unresectable Pancreatic Cancer

#UnresectablePancreaticCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
AntibodystaleNational Cancer Institute (NCI)Phase 1

Moxetumomab Pasudotox-tdfk (Moxetumomab Pasudotox-tdfk)

Hairy Cell Leukemia · Hairy Cell Leukemia

#HairyCellLeukemia#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 RECRUITING
CGTBiologicstaleNational Cancer Institute (NCI)Phase 2

Multi-epitope (ME, Multi-epitope, Multi-epitope (ME) T-cell receptor g alternate reading frame protein (TARP) vaccine)

Prostatic Neoplasms; Prostate Cancer · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4
효능 ORR 2.4%임상시험 1상태 DISCONTINUED
ADCBiologicstaleAcademic and Community Cancer R…Phase 2

Multi-epitope HER2 Peptide Vaccine TPIV100 (Multi-epitope HER2 Peptide Vaccine TPIV100)

Breast Adenocarcinoma; Stage II Breast Cancer AJCC v6 and v7 · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 ACTIVE
CGTBiologicstaleChanghai HospitalPhase 2

Mutant KRAS G12V-specific TCR transduced autologous T cells (Mutant KRAS G12V-specific TCR transduced autologous T cells)

Pancreatic Cancer; Pancreatic Neoplasms · Pancreatic Cancer

#PancreaticCancer#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
AntibodystaleImmunityBio, Inc.Phase 2

atezolizumab (Tecentriq, N-803 + Atezolizumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleImmunityBio, Inc.Phase 2

atezolizumab (Tecentriq, N-803 + Atezolizumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleImmunityBio, Inc.Phase 2

N-803 + Avelumab (N-803 + Avelumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 6%임상시험 1상태 RECRUITING
AntibodystaleImmunityBio, Inc.Phase 2

N-803 + Avelumab + PD-L1 t-haNK (N-803 + Avelumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#항체#면역항체+4
효능 ORR 6%임상시험 1상태 RECRUITING
AntibodystaleImmunityBio, Inc.Phase 2

nivolumab (Opdivo, N-803 + Docetaxel + Nivolumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, N-803 + Docetaxel + Pembrolizumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleImmunityBio, Inc.Phase 2

durvalumab (Imfinzi, N-803 + Durvalumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleImmunityBio, Inc.Phase 2

durvalumab (Imfinzi, N-803 + Durvalumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleImmunityBio, Inc.Phase 2

nivolumab (Opdivo, N-803 + Nivolumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, N-803 + Nivolumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleImmunityBio, Inc.Phase 2

pembrolizumab (Keytruda, N-803 + Pembrolizumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING

53 / 75 페이지

← 이전다음 →